A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD. METHODS: Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale-Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures. RESULTS: The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events. CONCLUSIONS: This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine's full potential as a treatment for chronic PTSD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of repeat-dose ketamine (six infusions over two weeks, n = 30) found a response rate of 67% [102]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“…were assessed before infusion and at 40 and 120 minutes after start of infusion with the Clinician-Administered Dissociative States Scale (28), the 4-item positive symptom subscale of the Brief Psychiatric Rating Scale (29), and the fi rst item (elevated mood) of the Young Mania Rating Scale (30).”
MethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…a rapid increase in glutamate release, triggering several downstream signaling pathways (including brain-derived neurotrophic factor [BDNF] and mammalian target of rapamycin complex 1 [mTORC1]), resulting in increased synaptogenesis and synaptic spine maturation in key brain regions (33, 34).”
BackgroundAssessing psychological trauma and PTSD
(1997) · Choice Reviews Online · doi:10.5860/choice.34-5966 · Cited by 2,330
Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018) · Psychological Assessment · doi:10.1037/pas0000486 · Cited by 1,799 · cited 15×
“The study involved three phases: 1) screening, during which participants were assessed for eligibility and any required medication tapering took place; 2) a 2-week treatment phase, during which participants received six in-fusionsofstudydrugapproximatelythreetimesperweekand were assessed on each infusion day, as well…”
MethodInfluentialTrauma and PTSD in the WHO World Mental Health Surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., Bromet, E. J., Cardoso, G., Degenhardt, L., de Girolamo, G., Dinolova, R. V., Ferry, F., et al. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2017.1353383 · Cited by 1,661 · cited 1×
“Rates vary by trauma type, severity, and cumulative trauma exposure, with the highest PTSD burden among survivors of interpersonal violence (2).”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 1×
“…to develop novel pharmacologic interventions for chronic PTSD. Ketamine, fi rstapprovedbytheFDAasananestheticagent in 1970 (11), is a noncompetitive glutamate N -methyl- D -as- partate (NMDA) receptor antagonist, with lower af fi nity for serotonin, dopamine, opioid, and other receptors (12).”
Background
Research works printed but not linked: 2
- Golier JA, 2012, Depress Res Treat, 2012, 393251
- First MB, 2015, Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)
Cited by
Items 101–200 of 246
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
Ramos, C. S., Thornburg, M., Long, K., Sharma, K., Roth, J., Lacatusu, D., Whitaker, R., Pacciulli, D., Loo, S. M., Manzoor, M., et al. (2022) · Cureus · doi:10.7759/cureus.23647 · Cited by 14
“Clinical trials were conducted in a regulated manner that demonstrated similar findings to those suggested by the Bluelight website retrospective study [50,51].”
BackgroundResultInfluentialDavis, A. K., Mangini, P., & Xin, Y. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00179 · Cited by 13
“After six infusions, the group that received ketamine demonstrated a stronger reduction in PTSD symptoms compared to the midazolam group (Feder et al., 2021).”
BackgroundRohde, J., Hickmann, E., Buchmann, M., Kronenberg, G., Vetter, S., Seifritz, E., Kleim, B., & Olbrich, S. (2024) · Behavioral Sciences · doi:10.3390/bs14080717 · Cited by 9
“Feder and colleagues demonstrated its efficacy through single and repeated intravenous doses of 0.5 mg/kg, showing rapid and safe symptom reduction within 24 h, but with limited duration [18,19].”
BackgroundInfluentialBeaglehole, B., Glue, P., Neehoff, S., Shadli, S. M., McNaughton, N., Kimber, B., Muirhead, C., de Bie, A., Day-Brown, R., & Medlicott, N. J. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10854 · Cited by 11
Korem, N., Duek, O. A., Ben‐Zion, Z., Spiller, T. R., Gordon, C., Amen, S. L., Levy, I., & Harpaz‐Rotem, I. (2024) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2024.111864 · Cited by 8
Koweszko, T., de Barbaro, B., Izydorczyk, B., Mastalerz–Migas, A., Samochowiec, J., Szulc, A., Kowalska, A., Wachowska, K., & Gałecki, P. (2023) · Psychiatria Polska · doi:10.12740/pp/166172 · Cited by 7
“Study by Feder et al. [70] proves the effectiveness of ketamine in reducing symptoms compared to the control group.”
Shiner, B. R., Huybrechts, K. F., Gui, J., Rozema, L. R., Forehand, J. A., Watts, B. V., Jiang, T., Hoyt, J. E., Esteves, J., Schnurr, P. P., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac104 · Cited by 11
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Glavonic, E., Dragić, M., Mitić, M., Aleksic, M., Lukić, I., Ivković, S., & Adžić, M. (2024) · Pharmaceuticals · doi:10.3390/ph17060669 · Cited by 7
“Regarding anxiety and PTSD, patients’ responsiveness to ketamine can vary between 67% [31,62] and 80% [30,63].”
BackgroundKetamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis
Kwan, A. T. H., Lakhani, M., Singh, G., Le, G. H., Wong, S., Teopiz, K. M., Dev, D. A., Manku, A. S., Sidhu, G., & McIntyre, R. S. (2024) · CNS Spectrums · doi:10.1017/s1092852924000580 · Cited by 14
The neuroscientific basis of post-traumatic stress disorder (PTSD): From brain to treatment
Agbaria, L., Mirzaei, F., A'amar, N. O., Raba, F. T., Papazian, G., Bhatnagar, K., Sirimanne, N., Ayoubkhan, A. A., Thilagendra, A. G., & Gupta, A. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.01.009 · Cited by 7
Butler, M., Seynaeve, M., Bradley‐Westguard, A., Bao, J., Crawshaw, A. A., Pick, S., Edwards, M. J., Nicholson, T. R., & Rucker, J. (2022) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21080213 · Cited by 7
Guidetti, C., Serra, G., Pani, L., Pappagallo, M., Maglio, G., Trasolini, M., Martin, S. D., Mattarei, A., Bifari, F., Folli, F. B., et al. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001583 · Cited by 7
Mertens, Y. L., Manthey, A., Sierk, A., de Jong, P. J., Walter, H., & Daniels, J. K. (2023) · BJPsych Open · doi:10.1192/bjo.2023.34 · Cited by 7
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
MacConnel, H. A., Earleywine, M., & Radowitz, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286726 · Cited by 9
“For example, intravenous ketamine significantly improved PTSD symptoms in a randomized controlled trial with 30 participants (Feder et al., 2021).”
Guida, C. R., Maia, J. M., Ferreira, L. F. R., Rahdar, A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111070 · Cited by 7
Praktische Aspekte der Ketaminbehandlung – Sicherheit, Kombinationstherapien und Komorbiditäten
Findeis, H., Ludwig, V. M., Mikoláš, P., Graff, J., Bauer, M., & Ritter, P. S. (2022) · Der Nervenarzt · doi:10.1007/s00115-021-01260-4 · Cited by 5
Trevino, C. M., Carver, T., Tomas, C. W., Larson, C., Mantz-Wichman, M., Peppard, W., & deRoon-Cassini, T. (2025) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004835 · Cited by 4
Valizadeh, A., Roache, J. D., Zhang, X., Hu, Y., Gueorguieva, R. V., Averill, L. A., Ranganathan, M., Wang, Z., Williamson, D. E., Shiroma, P. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114445 · Cited by 3
Obi, T., & Ressler, K. J. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02371-9 · Cited by 7
“The median time to loss of response among responders was approximately four weeks [88].”
Gausemel, Å., & Filkuková, P. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1291961 · Cited by 7
Fischman, L. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1469559 · Cited by 8
Coulon, N., Grenon, M., Consigny, M., & Simson, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.728133 · Cited by 5
“Furthermore, about care and therapeutics, a whole new literature is appearing: for example, current research focuses on the treatment with ketamine of major depressive episodes, suicidal ideation (42–44) and chronic PTSD (45, 46) in adult populations.”
BackgroundPosttraumatic Stress Disorder 101
Pary, R., & Lippmann, S. (2022) · Southern Medical Journal · doi:10.14423/smj.0000000000001469 · Cited by 6
Jones, J. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1096298 · Cited by 4
Titone, M. K., Hunt, C., Bismark, A. W., Nokes, B. T., Lee, E., Ramanathan, D., Park, J., & Colvonen, P. J. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10746 · Cited by 4
“20 These results, interestingly, correspond with some other open-label and clinical trials, showing that racemic intravenous ketamine has rapid-acting effects on reducing PTSD symptoms 14,21,22 in civilians.”
Geller, J. A., Keith, K., Smith, C., Pacilio, R. M., Arfken, C. L., Oxley, M., & Mischel, N. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100688 · Cited by 4
Ketamin und andere N-Methyl-D-Aspartat-Rezeptor-Modulatoren zur Behandlung der Depression
Vestring, S., Domschke, K., & Normann, C. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01221-x · Cited by 5
Rothärmel, M., Mékaoui, L., Kazour, F., Herrero, M., Beetz-Lobono, E.-M., Lengvenytė, A., Holtzmann, J., Raynaud, P., Cuenca, M., Bulteau, S., et al. (2024) · medRxiv · doi:10.1101/2024.01.09.24300998 · Cited by 4
Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of agingPreprint
Dawson, K., Carangan, A. M. J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R. C., et al. (2024) · medRxiv · doi:10.1101/2024.09.10.24313258 · Cited by 4
Wollenman, L. C., Tipold, A. M., Semler, M. W., Casey, J. D., Lacy, A. J., Self, W. H., Kiehl, A. L., Bryant, P. T., DeMasi, S. C., Stanley, I. H., et al. (2025) · CHEST Critical Care · doi:10.1016/j.chstcc.2025.100136 · Cited by 4
“15,16 However, the effect of ketamine on symptoms of PTSD after critical illness has not been evaluated.”
Effects of Intravenous Ketamine on Posttraumatic Stress Disorder ( PTSD ): A Systematic Review
Yin, L., Lu, A., Le, G. H., Dri, C. E., Wong, S., Teopiz, K. M., Xu, H., Ho, R., Rhee, T. G., Lo, H. K. Y., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70053 · Cited by 4
“Finally, examining ketamine responders in a multi-infusion study, the median time for responders to lose response after the primary outcome assessment day (2 weeks after the first infusion) was 27.5 days [47].”
InfluentialDodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
“115,145 A single ketamine infusion has demonstrated a fast onset of effect and a significant reduction in PTSD and depression related symptoms for an average response period of up to 7 days post-treatment.”
Laurin, A., Bottemanne, H., Bulteau, S., Haj, M. E., Sauvaget, A., & Deschamps, T. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106546 · Cited by 4
Hu, H., Lee, Y., Tillman, A. N., Ballard, E. D., Waldman, L. R., Yuan, P., Johnston, J. N., Peng, S., Kvarta, M. D., Verbalis, J. G., et al. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70133 · Cited by 3
“…given that repeated ketamine infusions, compared to a single infusion, have been associated with more sustained clinical improvement in both depression 89 and PTSD. 90 No differences were found in plasma copeptin levels between HVs and the MDE participants, regardless of MDD versus BD etiology.”
InfluentialLaurent, N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1755107 · Cited by 3
“More recently, ketamine has demonstrated rapid PTSD symptom relief, but concerns about long-term efficacy, dissociative effects, and potential addiction limit broader adoption (20–22).”
Neurobiology of Posttraumatic Stress Disorder: Circuits, Genomics, and Treatment
Beatty, Z. G., Kearney, M. G., Ponomareva, O. Y., & Ressler, K. J. (2026) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-102124-033854 · Cited by 6
Drožđek, B., & Rodenburg, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1356862 · Cited by 3
Elmaadawi, A. Z., Naha, I., Prabhudesai, S., & Eltohami, M. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116821 · Cited by 5
Clínicas de ketamina: usos actuales según la evidencia
Torres-Valdés, S. S., Carrillo-Torres, O., & Rascón-Martínez, D. M. (2023) · Revista Mexicana de Anestesiología · doi:10.35366/111076 · Cited by 7
“Se ha observado mejoría en los efectos positivos durante el inicio y mantenimiento de la abstinencia después de 12 semanas de tratamiento con ketamina y al combinar con terapia de mejora motivacional; los efectos psicoactivos/ místicos en el comportamiento propenso al alcohol fueron fundamentales para producir una red…”
BackgroundRojas, D., Zelman, D. C., Hauson, A. O., & Alexander, I. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2341811 · Cited by 4
“There are also promising preliminary findings for the treatment of post-traumatic stress disorder (PTSD, Feder et al. 2021; Ross et al. 2019), anxiety (Tully et al. 2022), substance use disorders (Jones et al. 2018) and eating disorders (Ragnhildstveit et al. 2022).”
Gupta, J. K., Singh, K., Bhatt, A., Porwal, P., Rani, R., Dubey, A., Jain, D., & Nand, S. (2024) · 3 Biotech · doi:10.1007/s13205-024-04104-5 · Cited by 5
“Conclusive data has shown that (R,S)- ketamine has both long-lasting and fast-acting antidepressant effects in depressed individuals, post-traumatic stress disorder (PTSD), and bipolar disorder (BD) who do not respond to conventional treatments (Hashimoto 2022; Feder et al. 2021; Fava et al. 2020).”
McInnes, L. A., Berman, R., Worley, M. J., & Shih, E. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116689 · Cited by 7
Fear-related anxiety disorders and posttraumatic stress disorder
Moreland-Capuia, A. R., Vahabzadeh, A., Gillespie, C. F., & Ressler, K. J. (2023) · Neurobiology of Brain Disorders · doi:10.1016/b978-0-323-85654-6.00005-8 · Cited by 3
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes, L. A., & Marton, T. F. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822284575240130053259 · Cited by 4
Zhang, S., Afshar, H. T., Colvonen, P. J., Nokes, B. T., Compton, J. N., Mishra, J., Bismark, A. W., Ramanathan, D., & Koloski, M. F. (2025) · CNS Drugs · doi:10.1007/s40263-025-01180-w · Cited by 6
“Ketamine and esketamine have shown promise in treating PTSD symptoms, with several studies reporting improvement in PCL-5 scores following both repeated IN esketamine and IV ketamine sessions [30, 43, 44].”
Post-traumatic stress disorder in psychedelic research
Bostoen, T., Tap, S. C., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.004 · Cited by 2
Dawson, K. L., Carangan, A. M. J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Perkins, N., Mendez, T. L., Smith, R. M., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03683-y · Cited by 9
Progress, potential and pitfalls of ketamine as a treatment for depression
Orsini, D. K., Luch, S. D. D., Lovell, G. F. M., & Rosenblat, J. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2637587 · Cited by 2
“Findings demonstrated significant changes in PTSD symptoms at the end of treatment across studies, the most notable being the first RCT to establish efficacy and safety of an acute course of treatment [86].”
Rothärmel, M., Mékaoui, L., Kazour, F., Herrero, M., Beetz-Lobono, E.-M., Lengvenytė, A., Holtzmann, J., Raynaud, P., Cuenca, M., Bulteau, S., et al. (2026) · European Journal of Psychotraumatology · doi:10.1080/20008066.2025.2609425 · Cited by 9
“Ketamine has also shown promising results in comorbid PTSD with treatment-resistant depression (TRD) (Albott et al., 2018) and in chronic PTSD alone (Duek et al., 2021; Feder et al., 2014; Feder et al., 2021; Pradhan et al., 2017), although some replications failed (Abdallah et al., 2022).”
Treating PTSD: A review of 8 studies
Saeed, S. A. (2023) · Current Psychiatry · doi:10.12788/cp.0324 · Cited by 3
Posttraumatic Stress Disorder (PTSD) and Trauma
Crombie, K. M., Cisler, J. M., & Nemeroff, C. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00007-5 · Cited by 2
Ishii, K., & Okita, K. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104164 · Cited by 2
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
Melnyk, M. I., Dryn, D. O., Dziuba, D. O., & Zholos, A. V. (2023) · Fìzìologìčnij žurnal · doi:10.15407/fz69.01.025 · Cited by 2
Pain specialist management of sexual pain–IV. Pharmacological
Vogel, J. J. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeac012 · Cited by 3
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Psychedelics as a treatment for patients with post-traumatic stress disorder (PTSD)
Marcinkowski, K., Mazur, A., Madera, M., Mazur, S., Strus, K., Bizan, A., Nagórska, E., Zdunek, R., Dąbrowska, N., & Kublińska, A. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.63.004 · Cited by 2
“Randomized assignment of 30 participants to either the 0.5 mg/kg ketamine hydrochloride group or the 0.045 mg/kg midazolam group, with the aim of controlling PTSD severity through the CAPS-5 and MADRS scales, along with monitoring substance-related adverse effects was conducted by Feder et al. [29].”
BackgroundMethodInfluentialAsimakopoulou, E., Theodosis‐Nobelos, P., & Triantis, C. (2024) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000139 · Cited by 2
Chen, B. K., Hunsberger, H. C., Whye, A., Matthews, L. C., Yook, A., Willner, M. J., Logan, R. W., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01804-9 · Cited by 3
“For combined K + P, K was administered once per week, consistent with previous studies [49, 50], and P was administered daily.”
Abreu, C. C., Biorac, A., Baldessarini, R. J., & Vázquez, G. H. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251392429 · Cited by 3
“…alongside oral antidepressants, esketamine demonstrated significant, although variable, clinical benefit in randomized trials, including for TRD. 19 Its approval marked both a regulatory milestone and a sign of shifting psychiatric paradigms, as agencies and clinicians began to embrace…”
Lemeshova, A., Patel, K. A., Bloom, A. J., Golan, L., Haidari, H., Limbada, A., Zhao, C., & Honeycutt, J. A. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174144 · Cited by 3
Thomas, J. E., Dellarole, A., & Caballero, J. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag062 · Cited by 2
Mei, X., Wu, H., Yuan, T., Samsom, J., Ying, S., Liu, X., Xu, T., Liu, F., & Shen, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03538-y · Cited by 2
From Bench to Bedside: Understanding General Anesthetics' Impact on PTSD
Li, K., Meimei, G., Wei, W., Li, X., & Peng, M. (2026) · Current Neuropharmacology · doi:10.2174/011570159x402072251103071408 · Cited by 1
Cheung, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1752101 · Cited by 8
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Koushik, S. S., Gritsenko, K., Binda, D. D., Daybell, I. S., Hill, N. S., Raghavan, J., Borukh, E., Smith, B. B., Kraus, M. B., & Shaparin, N. (2026) · CNS Drugs · doi:10.1007/s40263-026-01320-w · Cited by 1
“Beyond acting as an analgesic agent, ketamine has been shown to be effective for anesthetic induction, sedation, and treatment of several psychiatric conditions, including depression, anxiety, and PTSD [70, 71].”
Stirling, J., Doane, M. A., Simon, M. A., Shackel, R., & Elliott, J. M. (2026) · Australian and New Zealand Continence Journal · doi:10.1071/cj25013 · Cited by 1
The treatment of post-traumatic nightmares requires more attention
Kim, E. S., & Kang, C. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-00988-0 · Cited by 1
“RCT in pts aged 18–70 years with chronic PTSD related to a range of trauma exposures (n = 30) [31] Repeated IV infusions of ketamine 0.”
BackgroundMedications for Anxiety Disorders
Narita, Z. C., Fujimoto, M., Winter, E., Nestadt, P. S., & Sawa, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_136-1 · Cited by 1
Novel Mechanisms and Interventions for PTSD
(2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021010 · Cited by 1
Pharmakologische Behandlung der Posttraumatischen Belastungsstörung
Roepke, S., Schellong, J., Bergemann, N., Frommberger, U., & Schmidt, U. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01684-8 · Cited by 3
魏, 嘉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551503 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
A System for Rapidly Yet Rigorously Evaluating the Quality of Randomized Controlled Trials
Smith, E. G., & Grigorian, H. L. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001724 · Cited by 2
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Wellington, N. J., Bouças, A. P., Schwenn, P., Lagopoulos, J., Quigley, B. L., & Kuballa, A. (2025) · medRxiv · doi:10.1101/2025.05.25.25327632 · Cited by 1
Plöderl, M., Cooper, R. E., Walker, T., Shah, V., Horowitz, M. A., Volkmann, C., & Moncrieff, J. (2025) · medRxiv · doi:10.1101/2025.08.19.25333796 · Cited by 2
Cheung, N. V. (2025) · Research Square · doi:10.21203/rs.3.rs-8189081/v1 · Cited by 1
Psychedelics shift decision strategies and reconfigure orbitofrontal dynamics
Delgado-Sallent, C., Ahmed, S. A., Khawaja-Lopez, A., Lee, B. S., Mishra, U., Senne, R. A., Ramirez, S., & Scott, B. B. (2026) · Science Advances · doi:10.1101/2025.09.18.677110 · Cited by 3
“Psychedelics like psilocybin and ketamine have shown great potential in treating psychiatric disorders, often producing long-lasting effects after a single dose 1,2 .”
Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls
Garakani, A., Freire, R. C. R., & Murrough, J. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.662963 · Cited by 4
“are building upon previous research of another NMDA antagonist, ketamine, which has also been tested using IV infusions in patients with treatment-resistant depression (9–13), comorbid PTSD and MDD (14), and randomized controlled trials showing potential efficacy in PTSD as well (15, 16).”
BackgroundSelf-citationBarfety-Servignat, V., & Sallet, A. (2021) · Douleur et Analgésie · doi:10.3166/dea-2021-0154
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
Do baseline anxiety symptoms impact response to IV Ketamine in treatment resistant depression?
Schreiber, Z., Wang, C., Tan, A. C., Riva‐Posse, P., McDonald, W. M., Crowell, A. L., Hermida, A. P., & Hershenberg, R. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100253
Artin, H., Bentley, S., Mehaffey, E., Liu, F. X., Sojourner, K., Bismark, A. W., PRINTZ, D. J., Lee, E., Martis, B., Peralta, S. D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3928508
The Role(s) of Psychopharmacology in the Treatment of PTSD
Baig, M. R., & Roache, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00150-x · Cited by 1
Hodge, B., & Marsh, A. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818954-2.00018-3
Cabrera, J., & Marsh, A. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-818954-2.00017-1
Ketamin-Gabe wirksam bei chronischer PTBS
(2021) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1463-6013
Moussiopoulou, J., Slapakova, L., Kirsch, B., Mei, E. W. Y., & Schüle, C. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100110
Is Ketamine Infusion an Effective Treatment for Post-Traumatic Stress Disorder? A Meta-AnalysisPreprint
Mowdawalla, C., Pradhan, B., Mitrev, L. V., Hunter, K., Saracco, B., Kim, H. W., & van Helmond, N. (2023) · Research Square · doi:10.21203/rs.3.rs-3559310/v1 · Cited by 1
Biomedical and public health studies on susceptibility to post-traumatic stress disorder
Jowf, G. I. A. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230906ga
Improvement of Mental Health Symptoms in Response to Ketamine Therapy in Medicaid-Eligible Patients
Bonnett, C. J., Bonder, J. H., Jain, R., Stabbert, A., & Sayre, C. (2024) · Journal of Psychiatry and Mental Health · doi:10.16966/2474-7769.151
Belli, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-39854-4_21
Hunt, K. J. (2024) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/4284
Chapter 21. Ketamine and Esketamine
Mathai, D. S., & Mathew, S. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as21
Metadata
- Authors
- Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2021-02-01
- Volume
- 178
- Issue
- 2
- Pages
- 193-202
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3120445729
- Cited by
- 246
- References
- 37
- Citations by year
- 2026: 43 · 2025: 43 · 2024: 41 · 2023: 50 · 2022: 47 · 2021: 22
- FWCI
- 27.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- post-traumatic stress disorder, chronic PTSD, ketamine, treatment response durability, depression, adverse effects, pharmacotherapy
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Chronic Disease, Depression, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Stress Disorders, Post-Traumatic, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.